Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma

BMJ Case Reports

Volumn , Issue , 2009, Pages

  Kager, Liesbeth M ^a   Kersten, Marie Jose ^a   Kloppenborg, Raoul Peter ^a   Van Oers, Rien ^a   Van Den Born, Bert Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896532696     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.06.2009.1926     Document Type: Article

References (15)

1. Glusker P, Recht L, Lane B. Reversible posterior leucecephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354: 980-1. [CrossRef ] [Medline] [Web of Science]
2. Koopman M, Muller EW, Punt CJA. Reversible posterior leucencephalopathy syndrome caused by bev acizumab: report of a case. Dis Colon Rectum 2008; 51: 1425-6. [CrossRef ] [Medline] [Web of Science]
3. Peter S, Hausmann N, Schuster A, et al. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. Clin Experiment Opthalmol 2008; 36: 94-6. [CrossRef ] (Pubitemid 351285202)
4. Govindarajan R, Adusumilli J, Baxter DL, et al. Reversible poserior leucoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006; 25: e48. Search Google Scholar
5. Hinchey JA, Chaves C, Appignani B, et al. A reversible posterior leucencephalopathy syndrome. N Engl J Med 1996; 334: 494-500. [CrossRef ] [Medline] [Web of Science]
6. Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy: findings on CT, MR imaging and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992; 159: 379-83. [Medline] [Web of Science]
7. Edvinsson L, Owman C, Sjöberg NO. Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study . Brain Res 1976; 115: 377-93. [CrossRef ] [Medline] [Web of Science]
8. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17. [CrossRef ] [Medline] [Web of Science] (Pubitemid 36741588)
9. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184-91. [Abstract/FREE Full text] (Pubitemid 43166024)
10. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17. [CrossRef ] [Medline] [Web of Science]
11. Kelly K, Kalachand R, Murphy P. Bortezomib-induced reversible posterior leucoencephalopathy syndrome. Br J Haematol 2008; 141: 566. [CrossRef ] [Medline] (Pubitemid 351667623)
12. Argaw AT, Gurfein BT, Zhang Y, et al. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 2009; 106: 1977-82. [Abstract/FREE Full text]
13. Chi OZ, Hunter C, Liu X, et al. Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex. Neurol Res 2005; 27: 864-8 [CrossRef ] [Medline] [Web of Science] (Pubitemid 41790273)
14. Kimura R, Nakase H, Tamaki R, et al. Vascular endothelial growth factor antagonist reduces brain edema formation and venous infarction. Stroke 2005; 36: 1259-63. [Abstract/FREE Full text] (Pubitemid 40803474)
15. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193-201. [CrossRef ] [Medline]